
801.15 Delayed Data As of Nov 28 | ![]() Today’s Change | 668.00 Today|||52-Week Range 853.97 | +11.04% Year-to-Date |
Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study Nov 27 / Zacks.com - Paid Partner Content | HRMY vs. REGN: Which Stock Is the Better Value Option? Nov 21 / Zacks.com - Paid Partner Content |
Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How Nov 24 / Zacks.com - Paid Partner Content | Should You Invest in the iShares Biotechnology ETF (IBB)? Nov 20 / Zacks.com - Paid Partner Content |
Regeneron (REGN) Stock Rallies 10% YTD: What Lies Ahead? Nov 24 / Zacks.com - Paid Partner Content |
Previous close | 798.08 |
Today’s open | 795.96 |
Day’s range | 792.43 - 801.61 |
Volume | 18,223 |
Average volume (3 months) | 462,331 |
Market cap | $87.0B |
Earnings growth (last year) | -46.98% |
Earnings growth (this year) | -9.37% |
Earnings growth (next 5 years) | +2.38% |
Revenue growth (last year) | -24.26% |
P/E ratio | 22.9 |
Price/Sales | 6.73 |
Price/Book | 3.86 |
Today’s change | Today’s % change | |
---|---|---|
VRTXVertex Pharmaceutica... | -3.25 | -0.93% |
ZTSZoetis Inc | -1.81 | -1.01% |
---- | ||
BMYBristol-Myers Squibb | -0.10 | -0.20% |
Next reporting date | February 8, 2024 |
EPS forecast (this quarter) | $10.21 |
Annual revenue (last year) | $12.2B |
Annual profit (last year) | $4.3B |
Net profit margin | 35.64% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Tarrytown, New York |